Screening Breast MRI and Gadolinium Deposition: Cause for Concern?
Screening Breast MRI and Gadolinium Deposition: Cause for Concern?
复制标题
乳房 MRI 筛查和钆沉积：令人担忧的原因？
DOI：
10.1093/jbi/wbab074
复制
发表时间：
2021
影响因子：
1.5
通讯作者：
Colleen H. Neal
中科院分区：
文献类型：
--
作者：
Colleen H. Neal
钆基造影剂（GBCA）已在全球范围内使用了30多年，并已实现了挽救生命的诊断。对比增强乳腺MRI常被用作乳腺癌终生风险升高的女性的补充筛查。已有数据表明，给予的部分钆保留在肾功能正常患者的骨、皮肤、实体器官和脑组织中，尽管目前尚无关于这种保留的临床或生物学意义的可靠数据。与大环药物相比，线性GBCA与更高的钆潴留风险相关。在她们的一生中，筛查的妇女可能会接受高累积剂量的GBCA。因此，随着乳腺MRI筛查利用率的增加，在该患者人群中应谨慎使用GBCA。
Gadolinium-based contrast agents (GBCAs) have been used worldwide for over 30 years and have enabled lifesaving diagnoses. Contrast-enhanced breast MRI is frequently used as supplemental screening for women with an elevated lifetime risk of breast cancer. Data have emerged that indicate a fractional amount of administered gadolinium is retained in the bone, skin, solid organs, and brain tissues of patients with normal renal function, although there are currently no reliable data regarding the clinical or biological significance of this retention. Linear GBCAs are associated with a higher risk of gadolinium retention than macrocyclic agents. Over the course of their lives, screened women may receive high cumulative doses of GBCA. Therefore, as breast MRI screening utilization increases, thoughtful use of GBCA is indicated in this patient population.
影响因子：
39
作者：
Wernli, Karen J.;DeMartini, Wendy B.;Ichikawa, Laura;Lehman, Constance D.;Onega, Tracy;Kerlikowske, Karla;Henderson, Louise M.;Geller, Berta M.;Hofmann, Mike;Yankaskas, Bonnie C.
通讯作者：
Yankaskas, Bonnie C.
影响因子：
19.7
作者：
Chen, Yong;Panda, Ananya;Gulani, Vikas
通讯作者：
Gulani, Vikas
影响因子：
3.9
作者：
Panda A;Mehta BB;Coppo S;Jiang Y;Ma D;Seiberlich N;Griswold MA;Gulani V
通讯作者：
Gulani V